EDISON, N.J.--(BUSINESS WIRE)--Oceana Therapeutics – an acute-care specialty medical device and pharmaceutical company dedicated to setting new standards of therapeutic excellence for achieving optimal outcomes – today said it closed on the previously announced agreement with Q-Med AB for worldwide rights to Deflux® and Solesta™. As part of the transaction Oceana Therapeutics is acquiring Q-Med Scandinavia, Inc., which accounts for the majority of the business for Deflux and Solesta, as well as the exclusive rights to market, sell and distribute other potential products intended for the management of urological and gastroenterological conditions.
